3-dimethylamino-2,2-dimethyl-propionic acid | 127753-35-9

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-dimethylamino-2,2-dimethyl-propionic acid
• 英文别名: 3-Dimethylamino-2,2-dimethyl-propionsaeure；3-(dimethylamino)-2,2-dimethylpropanoic acid；Dimethylaminopivalinsaeure
• CAS: 127753-35-9
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: SWFRUSQUOVBPRQ-UHFFFAOYSA-N

物化性质

• 熔点：
  100 °C
• 沸点：
  212.1±23.0 °C(Predicted)
• 密度：
  0.994±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.6
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-dimethylamino-2,2-dimethyl-propionic acid 在 氯化亚砜 作用下， 生成 3-dimethylamino-2,2-dimethyl-propionyl chloride ; hydrochloride
  参考文献：
  名称：

  US2370015

  摘要：

  公开号：
• 作为产物：
  描述：

  3-dimethylamino-2,2-dimethyl-propionitrile 在 盐酸 作用下， 生成 3-dimethylamino-2,2-dimethyl-propionic acid
  参考文献：
  名称：

  Mannich; Wieder, Chemische Berichte, 1932, vol. 65, p. 385,389

  摘要：

  DOI：

文献信息

• [EN] FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE<br/>[FR] COMPOSÉS BICYCLIQUES FUSIONNÉS UTILISÉS COMME INHIBITEURS DE LA PI3 KINASE
  申请人：MERCK SERONO SA

  公开号：WO2010100144A1

  公开（公告）日：2010-09-10

  The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.

  该发明涉及用于调节磷脂酰肌醇3-激酶活性及相关疾病的化合物（I）的公式。
• One-pot synthesis of β-amino acid derivatives via addition of bis(O-silyl) ketene acetals on iminium salts
  作者：Roba Moumné、Bernard Denise、Andrée Parlier、Solange Lavielle、Henri Rudler、Philippe Karoyan

  DOI：10.1016/j.tetlet.2007.09.119

  日期：2007.11

  We report here our findings on a new and highly efficient strategy for the synthesis of β-amino acids involving the addition of bis(O-silyl) ketene acetals on Mannich type iminium electrophiles.

  我们在这里报告我们关于合成β-氨基酸的新高效策略的发现，该策略涉及在曼尼希（Mannich）型亚胺基亲电体上添加双（O-甲硅烷基）乙烯酮缩醛。
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DE LA DOULEUR
  申请人：HELLER ADAM

  公开号：WO2010017405A1

  公开（公告）日：2010-02-11

  The invention features methods, kits, and compositions for the treatment of pain.

  本发明涉及用于治疗疼痛的方法、试剂盒和组合物。
• Amelioration of cataracts, macular degeneration and other ophthalmic diseases
  申请人：Matier L. William

  公开号：US20050131025A1

  公开（公告）日：2005-06-16

  Ophthalmically acceptable compositions used in arresting the development of cataract, presbyopia, macular degeneration and other retinopathies, glaucoma, uveitis and various corneal disorders are disclosed. The compositions are also useful as a prophylactic treatment to prevent or delay development of age-related ocular disorders, which include cataracts, presbyopia, glaucoma and macular degeneration. The compositions comprise a pharmaceutically acceptable carrier or diluent and at least one compound having the formula: where R 1 and R 2 are, independently, H or C 1 to C 3 alkyl; R 3 and R 4 are, independently C 1 to C 3 alkyl; and where R 1 and R 2 , taken together, or R 3 and R 4 , taken together, or both may be cycloalkyl; R 5 is H, OH, or C 1 to C 6 alkyl; R 6 is or C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R 7 is C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R 6 and R 7 , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

  本发明涉及可用于阻止白内障、老视、黄斑变性和其他视网膜病变、青光眼、葡萄膜炎以及各种角膜疾病的眼科可接受的组合物。该组合物还可用作预防性治疗，以预防或延迟年龄相关的眼部疾病的发展，包括白内障、老视、青光眼和黄斑变性。该组合物包括一种药用可接受的载体或稀释剂和至少一种具有以下式子的化合物：其中R1和R2独立地为H或C1到C3烷基；R3和R4独立地为C1到C3烷基；而R1和R2一起取代，或R3和R4一起取代，或两者都可以是环烷基；R5为H、OH或C1到C6烷基；R6为C1到C6烷基、烯基、炔基或取代的烷基或烯基；R7为C1到C6烷基、烯基、炔基或取代的烷基或烯基，或者R6和R7，或者R5、R6和R7一起形成一个具有3到7个原子的环烷或杂环。
• Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases
  申请人：Matier William L.

  公开号：US20130131052A1

  公开（公告）日：2013-05-23

  Ophthalmically acceptable compositions used in arresting the development of cataracts or macular degeneration comprising a pharmaceutically acceptable carrier or diluent and a compound having the formula: where R 1 and R 2 are, independently, H or C 1 to C 3 alkyl; R 3 and R 4 are, independently C 1 to C 3 alkyl; and where R 1 and R 2 , taken together, or R 3 and R 4 , taken together, or both may be cycloalkyl; R 5 is H, OH, or C 1 to C 6 alkyl; R 6 is or C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl; R 7 is C 1 to C 6 alkyl, alkenyl, alkynyl, or substituted alkyl or alkenyl or where R 6 and R 7 , or R 5 , R 6 and R 7 , taken together, form a carbocycle or heterocycle having from 3 to 7 atoms in the ring.

  眼科可接受的组合物，用于阻止白内障或黄斑变性的发展，包括一种药学可接受的载体或稀释剂和一种具有以下化学式的化合物：其中R1和R2分别为H或C1到C3烷基；R3和R4分别为C1到C3烷基；且其中R1和R2，一起取或R3和R4，一起取或两者都可以是环烷基；R5为H，OH或C1到C6烷基；R6为C1到C6烷基，烯基，炔基或取代的烷基或烯基；R7为C1到C6烷基，烯基，炔基或取代的烷基或烯基，或者其中R6和R7，或R5，R6和R7一起形成具有3到7个原子的碳环或杂环。